Early Phase 1 Long COVID Trial, Recruiting NCT05656105 Sponsor: University of Alabama at Birmingham Condition: Long COVID
Back to Long Covid

Early Phase 1 Long COVID Trial, Recruiting

NCT05656105
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 65 years old
  • You are either a healthy volunteer OR you have been diagnosed with Long COVID (also called post-acute sequelae of SARS-CoV-2, or PASC)
  • A specific genetic test (related to a protein called TSPO) shows you are a "high" or "mixed" affinity binder (this will be tested as part of screening)
  • If you have Long COVID: you previously had a confirmed COVID-19 infection, and your neurological symptoms (such as brain fog, headaches, or other nerve-related issues) have been present for at least four weeks before joining the study
  • If you are a healthy volunteer: you have no neurological symptoms

Who may not be able to join:

  • You have a reason you cannot safely have an MRI scan (for example, certain metal implants)
  • You are pregnant
  • You are currently breastfeeding
  • Your medical condition is too severe to take part in the imaging/scanning portion of the study
  • You have a long-term infectious disease such as HIV or Hepatitis C
  • You have had a viral or bacterial illness needing medical treatment or antibiotics within the past month
  • You have been diagnosed with cancer, including leukemia
  • You have a blood disorder or a blood clotting disorder
  • You have an autoimmune disease — unless that condition is Multiple Sclerosis (MS), which is allowed
  • A pregnancy hormone test (urine or blood) comes back positive on or just before the procedure day
  • You are currently enrolled in another clinical trial using experimental treatments
  • You are currently taking any experimental treatments
  • The same TSPO genetic test shows you are a "low affinity binder" (confirm with trial site)
  • You report a history of moderate or severe traumatic brain injury
  • You report a history of whiplash injury
  • You report a history of Inflammatory Bowel Disease (IBD) — note: Irritable Bowel Syndrome (IBS) with no signs of inflammation is generally allowed
  • Your blood test results at screening fall outside acceptable ranges, including: high levels of inflammation markers, signs of infection or anemia, abnormal thyroid levels, fasting blood sugar above 100 mg/dL, or results suggesting organ damage (confirm specific values with trial site)
  • You have used illegal substances within the past 6 months
  • You have been diagnosed with Type 1 or Type 2 diabetes
  • If you are a healthy volunteer: you regularly take over-the-counter anti-inflammatory medications, painkillers (other than aspirin), or sleep aids

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Jonathan McConathy, MD, PhD, University of Alabama at Birmingham

Phone: 205-9961082

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Registry
ClinicalTrials.gov
Start date
10 November 2023
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Measurement of regional brain TSPO levels using PET in participants with neurological PASC and healthy volunteers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov